Mayo Clinic | Strategic Alliance Partners

July 29, 2024

Current screening protocols fail to catch a number of people carrying genetic mutations associated with hereditary breast and ovarian cancer syndrome.

July 25, 2024

Tanios Bekaii-Saab, MD, FACP, discusses next-generation sequencing and the development of RAS-targeted therapies in gastrointestinal cancers.

July 19, 2024

Tanios S. Bekaii-Saab, MD, FACP, details data from the ESOPEC trial in early-stage gastroesophageal cancers, and findings from Checkmate-9DW in HCC.

July 12, 2024

Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs.

June 15, 2024

Mayo Clinic researchers report on a new surgical platform used during surgery that informs decision-making about tumor treatment within minutes.

June 15, 2024

Zanubrutinib was associated with improved cost savings and quality-adjusted life year benefits vs acalabrutinib in B-cell malignancies.

June 12, 2024

Decreases in variant allele frequency in ctDNA were linked to improved CBR with imlunestrant in estrogen receptor–positive, HER2-negative breast cancer

June 12, 2024

Eric Winer, MD, discusses the safety and efficacy outcomes of the TakeAim Leukemia trial and future research with emavusertib in combination therapies.

May 30, 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

May 28, 2024

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.

May 23, 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

May 13, 2024

Melanoma is often detected later in people with darker skin complexions and the consequences can be devastating, a Mayo Clinic study reveals.

May 03, 2024

Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.

April 24, 2024

Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.

April 11, 2024

Matthew P. Goetz, MD, discusses pharmacokinetic data for neoadjuvant (Z)-endoxifen in estrogen receptor–positive, HER2-negative breast cancer.

April 06, 2024

Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.

March 28, 2024

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

March 28, 2024

Saad J. Kenderian, MB, CHB, discusses ongoing research taking place to potentially move liso-cel into earlier lines of therapy for patients with CLL.

March 25, 2024

Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.

March 20, 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 in Waldenström macroglobulinemia.